Here’s to making lasting memories

Once-daily IMBRUVICA® (ibrutinib) is the first FDA-approved therapy for adults with WM.

(Waldenström’s macroglobulinemia)



Talk to your doctor about whether IMBRUVICA® is right for you

Learn More

How does IMBRUVICA® work?

Learn how IMBRUVICA® is different than chemotherapy

Get Started


Get information about taking IMBRUVICA®

Learn More

Welcome to a different way of treating WM

Starting treatment is an important time in your journey with WM. This website will help you learn more about your condition and how IMBRUVICA® (ibrutinib) can help.

IMBRUVICA® works differently from chemotherapy. For more information on how IMBRUVICA® works, go to the How Does IMBRUVICA® Work? section.1

With IMBRUVICA®, there’s a once-daily oral treatment option available to treat adults with WM1

It is not known if IMBRUVICA® is safe and effective in children.

From the moment you’re prescribed IMBRUVICA®, IMBRUVICA® By Your Side provides resources and support for getting the help you may need during treatment.

Coverage and Cost

Confirm your coverage and out-of-pocket costs for IMBRUVICA®.

Support Communications

Receive periodic emails with tips and information about treatment.

IMBRUVICA® By Your Side Ambassadors*

Call a By Your Side Ambassador if you have questions about IMBRUVICA®.

*By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.

Pharmacyclics, an AbbVie Company, may collect your personal data through your online and offline interactions with us, including your contact, demographic, geolocation, and health-related data. We may also collect your online usage data automatically through cookies and similar technologies. We use this data for several purposes, such as to provide you with and improve our programs, services, and products, customize your experiences, and for research and analytics. We retain your personal data for as long as necessary to fulfill these purposes or to comply with our record retention obligations. We do not sell your personal data but may use and disclose your personal data with marketing and advertising partners to deliver you ads based on your interests inferred from your activity across other unaffiliated sites and services (“online targeted advertising”) and for website analytics. To opt out of the use or disclosure of your personal data for online targeted advertising or for website analytics, go to Your Privacy Choices on our website. For more information on the personal data categories we collect, the purposes for their collection, our disclosures to third parties, your data subject rights, and our data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose Personal Data section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at